Ipatasertib

Ipatasertib (GDC-0068, RO5532961, RG7440) is a small-molecule drug developed by Hoffmann-La Roche. Its target is AKT (the sponsor names AKT). ClinicalTrials.gov describes the intervention as: For participants 12-17 years of age, ipatasertib will be administered at the starting dose of 200 mg for participants \< 35 kg, 300 mg for participants ≥35 and \< 45 kg, 400 mg for those ≥ 45 kg orally QD, beginning of Cycle 1, on Days 1-21. It is the investigational product in 5 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT05862285 (A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study), in HR-positive / HER2-negative breast cancer and ovarian cancer. The largest, NCT03424005, plans to enrol 1132 participants with primary completion expected 2030-09-30. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.